|
Date
of Proposal: April 7, 2008
Proposal
Number: PRN 2008-96
Proposal
Description: The proposal is to
amend N.J.A.C. 13:70-14A.9 to authorize
the continuing use of aminocaproic acid
(AMICAR) with Furosemide (LASIX) as an adjunct
medication to treat respiratory bleeding
in thoroughbred race horses that have been
placed on the Furosemide list. Because of
uncertainty regarding the effectiveness
of AMICAR in treating exercise-induced pulmonary
hemorrhage, the Racing Commission originally
authorized the
use of AMICAR only until Dec. 31, 2007.
By doing so, the Commission hoped for the
development of scientific evidence either
supporting the medical use of AMICAR or
determining that its use is not recommended.
To date, however, no body of evidence has
materialized to establish AMICAR’s
therapeutic value or show that it causes
harmful side effects. In proposing the current
amendment to allow for continued use of
AMICAR,
the Commission anticipates that the racing
industry’s experience in using AMICAR
in 2007 will generate meaningful public
comment as to whether the drug’s use
in New Jersey has been a positive or negative
experience.
The
public comment period will also allow interested
parties to submit research studies from
other jurisdictions that are published,
or otherwise recognized by the academic
community
as completed. Following the 60-day comment
period, the Commission will evaluate all
available information and decide whether
to adopt a rule permanently authorizing
the use of AMICAR. The proposed amendment
appears in the April 7, 2008 edition of
the New Jersey Register.
Summary
of Proposal: A detailed summary
of the proposed rule is posted on the New
Jersey Racing Commission Web site at: www.njpublicsafety.org/racing/proposed.html
Public
Comment: Public comment on the
proposed rule will be accepted until
June 6, 2008. Please direct all comments
to:
Michael
Vukcevich, Deputy Director
New Jersey Racing Commission
Department of Law and Public Safety
P.O. Box 088, Trenton, New Jersey 08625-0088
# # # |
